(UroToday.com) The 2026 European Association of Urology (EAU) annual meeting featured a high-risk non-muscle invasive bladder cancer session and a presentation by Dr. Dingwei Ye discussing results of ...
Continued maintenance BCG might be considered in BCG-responsive patients with very high-risk NMIBC without adverse clinical and pathologic features. Rather than undergo upfront radical cystectomy, ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
Chemohyperthermia Safe, Effective for NMIBC Adjuvant Treatment Patients who received BCG induction within 3 weeks or 3 weeks or more after surgery for nonmuscle-invasive bladder cancer did not differ ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
The FDA approved nogapendekin alfa inbakicept (Anktiva) for bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC), the agency announced Monday. A first-in-class ...
There are many reasons to have urology surgery. For example, your surgeon may operate to remove kidney stones, treat infertility, or manage urinary incontinence. Urologic surgeons treat patients of ...
Patients with Bacillus Calmette Guérin-unresponsive carcinoma in-situ will be treated at the University of Chicago in a Theralase study. The University of Chicago Medicine received approval from the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results